Fiskus, Warren http://orcid.org/0000-0002-7343-6214
Daver, Naval http://orcid.org/0000-0001-7103-373X
Boettcher, Steffen http://orcid.org/0000-0001-9937-0957
Mill, Christopher P.
Sasaki, Koji http://orcid.org/0000-0002-9140-0610
Birdwell, Christine E.
Davis, John A.
Das, Kaberi http://orcid.org/0000-0003-4702-0386
Takahashi, Koichi http://orcid.org/0000-0002-8027-9659
Kadia, Tapan M. http://orcid.org/0000-0002-9892-9832
DiNardo, Courtney D. http://orcid.org/0000-0001-9003-0390
Burrows, Francis
Loghavi, Sanam http://orcid.org/0000-0001-8980-3202
Khoury, Joseph D. http://orcid.org/0000-0003-2621-3584
Ebert, Benjamin L. http://orcid.org/0000-0003-0197-5451
Bhalla, Kapil N. http://orcid.org/0000-0001-5209-5126
Article History
Received: 12 July 2022
Revised: 8 September 2022
Accepted: 9 September 2022
First Online: 23 September 2022
Competing interests
: FB is an employee of Kura Oncology, Inc. BLE has received research funding from Celgene, Deerfield, Novartis, and Calico; and he is a member of the scientific advisory board and shareholder for Neomorph Therapeutics, Skyhawk Therapeutics, and Exo Therapeutics, none of which are directly related to the content of this paper. All other authors declare they have no financial interests to disclose.